Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening

被引：47

作者：

Usui, Taikou ^{[1
]}

Ban, Hyun Seung ^{[1
]}

Kawada, Junpei ^{[1
]}

Hirokawa, Takatsugu ^{[2
]}

Nakamura, Hiroyuki ^{[1
]}

机构：

[1] Gakushuin Univ, Fac Sci, Dept Chem, Tokyo 1718588, Japan

[2] Inst Adv Ind Sci & Technol AIST, Computat Biol Res Ctr, Tokyo 1350064, Japan

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2008年 / 18卷 / 01期

关键词：

D O I：

10.1016/j.bmcl.2007.10.084

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of indenopyrazoles 8 and 9 were designed and synthesized as EGFR tyrosine kinase inhibitors by in silico high-throughput screening. Compounds 8b and 8d showed significant inhibition of A431 cell growth (GI(50) = 0.062 and 0.057 mu M, respectively). Compounds 8b and 9a showed inhibitory activity toward both EGFR and VEGFR-2 (KDR) tyrosine kinases, whereas 8d inhibited VEGFR-2 tyrosine kinase, exclusively. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：285 / 288

页数：4

共 27 条

[11] Developing inhibitors of the epidermal growth factor receptor for cancer treatment [J].

Grünwald, V ;

Hidalgo, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (12) :851-867

[12] Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening [J].

Halgren, TA ;

Murphy, RB ;

Friesner, RA ;

Beard, HS ;

Frye, LL ;

Pollard, WT ;

Banks, JL .

JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (07) :1750-1759

[13]

HARRIS PA, 2005, J MED CHEM, V16, P10

[14] Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial [J].

Kris, MG ;

Natale, RB ;

Herbst, RS ;

Lynch, TJ ;

Prager, D ;

Belani, CP ;

Schiller, JH ;

Kelly, K ;

Spiridonidis, H ;

Sandler, A ;

Albain, KS ;

Cella, D ;

Wolf, MK ;

Averbuch, SD ;

Ochs, JJ ;

Kay, AC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16) :2149-2158

[15] Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib [J].

Kwak, EL ;

Sordella, R ;

Bell, DW ;

Godin-Heymann, N ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Driscoll, DR ;

Fidias, P ;

Lynch, TJ ;

Rabindran, SK ;

McGinnis, JP ;

Wissner, A ;

Sharma, SV ;

Isselbacher, KJ ;

Settleman, J ;

Haber, DA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (21) :7665-7670

[16] Protein kinase inhibitors: The tyrosine-specific protein kinases [J].

Lawrence, DS ;

Niu, JK .

PHARMACOLOGY & THERAPEUTICS, 1998, 77 (02) :81-114

[17] Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases [J].

Nakamura, Hiroyuki ;

Sasaki, Yusuke ;

Uno, Masaharu ;

Yoshikawa, Tomohiro ;

Asano, Toru ;

Ban, Hyun Seung ;

Fukazawa, Hidesuke ;

Shibuya, Masabumi ;

Uehara, Yoshimasa .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (19) :5127-5131

[18] Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 2. Probing the indeno ring substituent pattern [J].

Nugiel, DA ;

Vidwans, A ;

Etzkorn, AM ;

Rossi, KA ;

Benfield, PA ;

Burton, CR ;

Cox, S ;

Doleniak, D ;

Seitz, SP .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (24) :5224-5232

[19] Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors [J].

Nugiel, DA ;

Etzkorn, AM ;

Vidwans, A ;

Benfield, PA ;

Boisclair, M ;

Burton, CR ;

Cox, S ;

Czerniak, PM ;

Doleniak, D ;

Seitz, SP .

JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (09) :1334-1336

[20] Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer [J].

Pérez-Soler, R ;

Chachoua, A ;

Hammond, LA ;

Rowinsky, EK ;

Huberman, M ;

Karp, D ;

Rigas, J ;

Clark, GM ;

Santabàrbara, P ;

Bonomi, P .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3238-3247

← 1 2 3 →